Adma Biologics Stock News

Can these penny stocks continue to climb after a bearish trading day? The post Best Penny Stocks to Watch After the Stock Market Takes a Bear Turn appeared first on Penny Stocks to Buy, Picks, News an

RAMSEY, N.J. and BOCA RATON, Fla., April 01, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedica

ADMA reported full-year 2021 numbers on March 24, which disclosed higher than expected revenue, a lower than expected net loss, and strong 2022 guidance.

Are these penny stocks on your April watchlist? The post Top Must-Watch Penny Stocks For Your April List  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are these penny stocks on your April watchlist? The post Top Must-Watch Penny Stocks For Your April List  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Approval of 36-month shelf life encompasses all ASCENIV & BIVIGAM vial sizes, production scales, as well as internal and external fill-finishing

ADMA Biologics Inc (NASDAQ: ADMA) closed a debt refinancing with Hayfin Capital Management of $150 million, and up to an additional $25 million tied to specific revenue targets during 2022. The first

Adma Biologics (ADMA) delivered earnings and revenue surprises of 10% and 1.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Full Year 2021 Total Revenues of Approximately $81 Million, a 92% Increase Over Full Year 2020

Adma Biologics (ADMA) delivered earnings and revenue surprises of 10% and 1.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Conference Call Scheduled for March 24, 2022 at 4:30 p.m. ET Conference Call Scheduled for March 24, 2022 at 4:30 p.m. ET

Conference Call Scheduled for March 24, 2022 at 4:30 p.m. ET Conference Call Scheduled for March 24, 2022 at 4:30 p.m. ET

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative Options For Infectious Diseas

Here''s a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative Options For Infectious Diseases Moderna, Inc. (NASDAQ: MRNA ) announced four initiatives to advance mRNA vaccines to prevent infectious diseases. They include its global public health portfolio to 15 vaccine programs and setting up the mRNA Access to provide its mRNA technology to researchers to explore new vaccines against emerging or neglected infectious diseases. Additionally, the company said it has resolved not to enforce its COVID patents in the Gavi COVAX AMC for 92 low- and middle-income countries. The company also said, with the assistance of the U.S. government, it has entered into a memorandum of understanding with Kenya to establish Kenya as the location for its mRNA manufacturing facility. Mallinckrodt Agrees To Pay $234M To Settle Lawsuit Alleging Underpayment Of Medicaid Drug Rebates Mallinckrodt plc (OTC: MNKKQ ) has agreed to pay $234 million to settle false claims act case brought by Whistleblower Law Collaborative regarding underpayment of Medicaid rebates for its drug Acthar.

FDA approval supports corporate goal of plasma supply self-sufficiency and ongoing revenue growth Company positioned to meet or exceed target of 10 or more FDA-approved plasma collection centers by y